Breast Cancer Medical Coding: What the Statistics Mean

Breast cancer statistics help medical coders anticipate the documentation and coding decisions they will encounter most often, including invasive versus in situ disease, lymph node involvement, receptor status, long-term treatment, and personal history. Accurate ICD-10-CM reporting supports claims, quality reporting, cancer registries, and research while helping healthcare organizations maintain revenue cycle and clinical data integrity.

Every October, Breast Cancer Awareness Month puts the spotlight on patients, survivors, and the care teams who support them. Health information (HI) professionals are part of that team. Each breast cancer diagnosis generates years of encounters: screening, biopsy, surgery, systemic therapy, reconstruction, and surveillance. Every one of those encounters must be coded accurately for claims, quality reporting, cancer registries, and research.

The numbers show why this matters. Breast cancer is one of the highest-volume diagnoses in U.S. oncology, and it is also one of the most varied. The type of cancer, its receptor status, and its stage all affect treatment, and most of them affect the medical code as well.

Breast cancer in the U.S.: 2026 at a glance

Sources: American Cancer Society, Cancer Facts & Figures 2026 and Key Statistics for Breast Cancer; NCI SEER Cancer Stat Facts: Female Breast Cancer.

Breast cancer is the most commonly diagnosed cancer in American women other than skin cancer. It makes up about one-third of new female cancer diagnoses and 15.2% of all new cancer cases in the U.S. The median age at diagnosis is 64. Incidence has been rising about 0.7% per year, and faster among women under 50, at about 1.4% per year. Death rates have fallen about 1.2% per year over the past decade.

That combination creates a large and growing survivor population, which has a direct effect on medical coding. More survivors mean more surveillance visits, more long-term hormone therapy, more reconstruction encounters, and more chances to confuse an active cancer with a personal history of one.

How stage diagnosis affects breast cancer coding

According to National Cancer Institute SEER data, most breast cancers are found early, and survival depends heavily on stage:

All stages — 91.9% Source: NCI SE

ER Cancer Stat Facts, Female Breast Cancer (survival 2016–2022).

Coding takeaway: A regional-stage cancer has already spread, which usually means lymph node involvement. When the provider documents nodal spread, it is reported as a secondary malignancy (for example, C77.3 for axillary lymph nodes) in addition to the primary C50 code, even though the patient is not stage IV. A stage by itself never supplies a secondary-site code. The provider must document where the cancer has spread.

ICD-10-CM codes for major breast cancer types

Breast cancers are classified by where they start (ducts or lobules) and by whether they are in situ (confined to where they began) or invasive (grown into surrounding tissue). That second distinction decides whether the code comes from the C50 category or the D05 category.

Sources: American Cancer Society; Breastcancer.org; ICD-10-CM FY2026 Tabular List.

Breast cancer receptor stats and Z codes

In addition to identifying where a cancer starts, oncologists classify it by receptors: estrogen (ER), progesterone (PR), and HER2. Receptor status determines whether hormone therapy or HER2-targeted drugs will work, and ICD-10-CM has status codes for each of them.

Source: NCI SEER Cancer Stat Facts, Female Breast Cancer Subtypes (cases 2019–2023; survival 2016–2022). Remaining cases have unknown subtype.

Seven in ten breast cancers are hormone receptor–positive, and many of those patients take tamoxifen or an aromatase inhibitor for five to ten years. That long treatment window is where coding most often goes wrong. While hormone therapy continues, the patient is still receiving treatment directed at the cancer, so the malignancy is coded as current (active), even when the record says “no evidence of disease” or describes the drug as preventing recurrence. Report long-term drug use with Z79.810 (selective estrogen receptor modulators such as tamoxifen) or Z79.811 (aromatase inhibitors). Move to Z85.3, personal history of breast cancer, only after all treatment is complete.

Triple-negative breast cancer is more aggressive and more common in people with BRCA1 mutations. When genetic susceptibility is documented, add Z15.01. For family history, add Z80.3.

Five common breast cancer medical coding errors

1. Coding DCIS as invasive cancer. More than 60,000 DCIS cases a year means this happens a lot. “Intraductal” or “in situ” anywhere in the record points to D05, not C50.
2. Assigning Z85.3 too early. With more than 4 million survivors and multi-year hormone therapy, coders have to confirm that all treatment has ended before switching to history.
3. Missing nodal involvement. About 27% of cases are regional at diagnosis. Documented lymph node spread needs its own secondary code.
4. Leaving out receptor status. With four distinct subtypes, Z17 status codes support medical necessity for targeted and hormone therapies and improve data quality.
5. Defaulting to unspecified site or sex. Quadrant, clock position, laterality, and sex are usually in the record. C50.919 should be the exception, not the rule.

Breast cancer coding frequently asked questions